You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePeginterferon alfa-2b
Accession NumberDB00022  (BTD00048, BIOD00048)
TypeBiotech
GroupsApproved
DescriptionPeginterferon alfa-2b is a covalent conjugate of recombinant alfa-2b interferon with monomethoxy polyethylene glycol (PEG). The average molecular weight of the PEG portion of the molecule is 12,000 daltons. The average molecular weight of the PEG-Intron molecule is approximately 31,000 daltons. The specific activity of peginterferon alfa-2b is approximately 0.7 x 108 IU/mg protein. Interferon alfa-2b is a water-soluble protein with a molecular weight of 19,271 daltons produced by recombinant DNA techniques. It is obtained from the bacterial fermentation of a strain of Escherichia coli bearing a genetically engineered plasmid containing an interferon gene from human leukocytes. The PEG strand protects the molecule in vivo from proteolytic breakdown, substantially increases its in vivo half-life, and reduces immunogenicity by wrapping around and physically hindering access to the protein portion of the molecule.
Protein structureDb00022
Related Articles
Protein chemical formulaNot Available
Protein average weight31000.0 Da
Sequences
>DB00022 sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
Download FASTA Format
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PegintronInjection, powder, lyophilized, for solution50 ug/.5mLSubcutaneousMerck Sharp & Dohme Corp.2001-01-19Not applicableUs
PegintronKitMerck Sharp & Dohme Corp.2014-08-11Not applicableUs
PegintronKitMerck Sharp & Dohme Corp.2001-01-19Not applicableUs
PegintronKitMerck Sharp & Dohme Corp.2001-01-19Not applicableUs
PegintronKitMerck Sharp & Dohme Corp.2001-01-19Not applicableUs
PegintronKitMerck Sharp & Dohme Corp.2014-08-11Not applicableUs
PegintronInjection, powder, lyophilized, for solution150 ug/.5mLSubcutaneousMerck Sharp & Dohme Corp.2001-01-19Not applicableUs
PegintronKitMerck Sharp & Dohme Corp.2014-08-11Not applicableUs
PegintronKitMerck Sharp & Dohme Corp.2001-01-19Not applicableUs
PegintronInjection, powder, lyophilized, for solution80 ug/.5mLSubcutaneousMerck Sharp & Dohme Corp.2001-01-19Not applicableUs
PegintronInjection, powder, lyophilized, for solution120 ug/.5mLSubcutaneousMerck Sharp & Dohme Corp.2001-01-19Not applicableUs
PegintronKitMerck Sharp & Dohme Corp.2014-08-11Not applicableUs
SylatronKitMerck Sharp & Dohme Corp.2014-08-30Not applicableUs
SylatronKitMerck Sharp & Dohme Corp.2011-03-29Not applicableUs
SylatronKitMerck Sharp & Dohme Corp.2011-03-29Not applicableUs
SylatronKitMerck Sharp & Dohme Corp.2011-03-29Not applicableUs
SylatronKitMerck Sharp & Dohme Corp.2011-03-29Not applicableUs
SylatronKitMerck Sharp & Dohme Corp.2011-03-29Not applicableUs
Unitron PegPowder, for solution118.4 mcgSubcutaneousMerck Canada Inc2001-03-272012-02-01Canada
Unitron PegPowder, for solution177.6 mcgSubcutaneousMerck Canada Inc2001-03-272012-02-01Canada
Unitron PegPowder, for solution222 mcgSubcutaneousMerck Canada Inc2001-03-272012-02-01Canada
Unitron PegPowder, for solution74 mcgSubcutaneousMerck Canada Inc2001-03-272012-02-01Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PEG-IntronSchering Corp
Brand mixtures
NameLabellerIngredients
PegetronMerck Canada Inc
Victrelis TripleMerck Canada Inc
SaltsNot Available
Categories
UNIIG8RGG88B68
CAS number215647-85-1
Pharmacology
IndicationFor the treatment of chronic hepatitis C in patients not previously treated with interferon alpha who have compensated liver disease and are at least 18 years of age.
Structured Indications
PharmacodynamicsUpregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.
Mechanism of actionInterferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.
TargetKindPharmacological actionActionsOrganismUniProt ID
Interferon alpha/beta receptor 1Proteinyes
agonist
HumanP17181 details
Interferon alpha/beta receptor 2Proteinyes
agonist
HumanP48551 details
Related Articles
AbsorptionFollowing a single subcutaneous dose of peginterferon alfa-2b, the mean absorption half-life (t½ ka) was 4.6 hours.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationRenal elimination accounts for 30% of the clearance.
Half lifeThe mean elimination half-life is approximately 40 hours (range 22 to 60 hours) in patients with HCV infection.
Clearance
  • Oral cl=22 mL/hr∙kg [patients with HCV infection]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe serum concentration of 4-Methoxyamphetamine can be decreased when it is combined with Peginterferon alfa-2b.Experimental, Illicit
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Peginterferon alfa-2b.Approved
AcetylcholineThe serum concentration of Acetylcholine can be decreased when it is combined with Peginterferon alfa-2b.Approved
AjmalineThe serum concentration of Ajmaline can be decreased when it is combined with Peginterferon alfa-2b.Approved
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Peginterferon alfa-2b.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Peginterferon alfa-2b.Experimental
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Peginterferon alfa-2b.Approved
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Peginterferon alfa-2b.Approved
AmoxapineThe serum concentration of Amoxapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
AmphetamineThe serum concentration of Amphetamine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Peginterferon alfa-2b.Approved
AmsacrineThe serum concentration of Amsacrine can be decreased when it is combined with Peginterferon alfa-2b.Approved
AnagrelideThe serum concentration of Anagrelide can be increased when it is combined with Peginterferon alfa-2b.Approved
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Peginterferon alfa-2b.Approved
AprepitantThe serum concentration of Aprepitant can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AprindineThe serum concentration of Aprindine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ArformoterolThe serum concentration of Arformoterol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Peginterferon alfa-2b.Approved
ASA404The serum concentration of ASA404 can be increased when it is combined with Peginterferon alfa-2b.Investigational
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Peginterferon alfa-2b.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
AtomoxetineThe serum concentration of Atomoxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
AV650The serum concentration of AV650 can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Peginterferon alfa-2b.Approved
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Peginterferon alfa-2b.Investigational
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
BenzatropineThe serum concentration of Benzatropine can be decreased when it is combined with Peginterferon alfa-2b.Approved
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Peginterferon alfa-2b.Approved
BepridilThe serum concentration of Bepridil can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
BetaxololThe serum concentration of Betaxolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Peginterferon alfa-2b.Approved
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Peginterferon alfa-2b.Approved, Illicit
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Peginterferon alfa-2b.Experimental, Investigational
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Peginterferon alfa-2b.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Peginterferon alfa-2b.Approved
CaptoprilThe serum concentration of Captopril can be decreased when it is combined with Peginterferon alfa-2b.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
CarmustineThe serum concentration of Carmustine can be increased when it is combined with Peginterferon alfa-2b.Approved
CarteololThe serum concentration of Carteolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Peginterferon alfa-2b.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Peginterferon alfa-2b.Approved
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Peginterferon alfa-2b.Approved
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Peginterferon alfa-2b.Approved
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Peginterferon alfa-2b.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Peginterferon alfa-2b.Approved
ClenbuterolThe serum concentration of Clenbuterol can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ClevidipineThe serum concentration of Clevidipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Peginterferon alfa-2b.Approved, Nutraceutical
ClozapineThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Clozapine.Approved
CodeineThe serum concentration of Codeine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Peginterferon alfa-2b.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Peginterferon alfa-2b.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
DacarbazineThe serum concentration of Dacarbazine can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Peginterferon alfa-2b.Approved
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Peginterferon alfa-2b.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Peginterferon alfa-2b.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Peginterferon alfa-2b.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Peginterferon alfa-2b.Approved
DesipramineThe serum concentration of Desipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
DexfenfluramineThe serum concentration of Dexfenfluramine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit, Withdrawn
DexmethylphenidateThe serum concentration of Dexmethylphenidate can be decreased when it is combined with Peginterferon alfa-2b.Approved
DextroamphetamineThe serum concentration of Dextroamphetamine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Peginterferon alfa-2b.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Peginterferon alfa-2b.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Peginterferon alfa-2b.Approved
DinoprostoneThe serum concentration of Dinoprostone can be increased when it is combined with Peginterferon alfa-2b.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Peginterferon alfa-2b.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Peginterferon alfa-2b.Approved
DopamineThe serum concentration of Dopamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
DoxazosinThe serum concentration of Doxazosin can be decreased when it is combined with Peginterferon alfa-2b.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Peginterferon alfa-2b.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Peginterferon alfa-2b.Approved
DuloxetineThe serum concentration of Duloxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Peginterferon alfa-2b.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Peginterferon alfa-2b.Approved
EltrombopagThe serum concentration of Eltrombopag can be increased when it is combined with Peginterferon alfa-2b.Approved
EncainideThe serum concentration of Encainide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
EnclomipheneThe serum concentration of Enclomiphene can be decreased when it is combined with Peginterferon alfa-2b.Investigational
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Peginterferon alfa-2b.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
EsmirtazapineThe serum concentration of Esmirtazapine can be decreased when it is combined with Peginterferon alfa-2b.Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Peginterferon alfa-2b.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Peginterferon alfa-2b.Approved
EthanolThe serum concentration of Ethanol can be increased when it is combined with Peginterferon alfa-2b.Approved
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Peginterferon alfa-2b.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Peginterferon alfa-2b.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
FlecainideThe serum concentration of Flecainide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Peginterferon alfa-2b.Approved
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Peginterferon alfa-2b.Approved, Illicit
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Peginterferon alfa-2b.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
FluphenazineThe serum concentration of Fluphenazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Peginterferon alfa-2b.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Peginterferon alfa-2b.Approved
FluvoxamineThe serum concentration of Fluvoxamine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
FormoterolThe serum concentration of Formoterol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
GenisteinThe serum concentration of Genistein can be increased when it is combined with Peginterferon alfa-2b.Investigational
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Peginterferon alfa-2b.Withdrawn
GuanabenzThe serum concentration of Guanabenz can be increased when it is combined with Peginterferon alfa-2b.Approved
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Peginterferon alfa-2b.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
HesperetinThe serum concentration of Hesperetin can be increased when it is combined with Peginterferon alfa-2b.Approved
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Peginterferon alfa-2b.Approved
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
IdarubicinThe serum concentration of Idarubicin can be decreased when it is combined with Peginterferon alfa-2b.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Peginterferon alfa-2b.Approved
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Peginterferon alfa-2b.Approved
LabetalolThe serum concentration of Labetalol can be decreased when it is combined with Peginterferon alfa-2b.Approved
LeflunomideThe serum concentration of Leflunomide can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Peginterferon alfa-2b.Approved
LevodopaThe serum concentration of Levodopa can be decreased when it is combined with Peginterferon alfa-2b.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Peginterferon alfa-2b.Approved
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Peginterferon alfa-2b.Approved
LomefloxacinThe serum concentration of Lomefloxacin can be increased when it is combined with Peginterferon alfa-2b.Approved
LomustineThe serum concentration of Lomustine can be decreased when it is combined with Peginterferon alfa-2b.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Peginterferon alfa-2b.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Peginterferon alfa-2b.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Peginterferon alfa-2b.Approved
LumiracoxibThe serum concentration of Lumiracoxib can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
MalathionThe serum concentration of Malathion can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
MaprotilineThe serum concentration of Maprotiline can be decreased when it is combined with Peginterferon alfa-2b.Approved
MelatoninThe serum concentration of Melatonin can be increased when it is combined with Peginterferon alfa-2b.Approved, Nutraceutical, Vet Approved
MenadioneThe serum concentration of Menadione can be increased when it is combined with Peginterferon alfa-2b.Approved, Nutraceutical
MephenytoinThe serum concentration of Mephenytoin can be decreased when it is combined with Peginterferon alfa-2b.Investigational, Withdrawn
MequitazineThe serum concentration of Mequitazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MesoridazineThe serum concentration of Mesoridazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Peginterferon alfa-2b.Withdrawn
MethadoneThe serum concentration of Methadone can be increased when it is combined with Peginterferon alfa-2b.Approved
MethamphetamineThe serum concentration of Methamphetamine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit
MethotrimeprazineThe serum concentration of Methotrimeprazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
MethylphenidateThe serum concentration of Methylphenidate can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
MethyprylonThe serum concentration of Methyprylon can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit, Withdrawn
MetoclopramideThe serum concentration of Metoclopramide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Peginterferon alfa-2b.Approved
MinaprineThe serum concentration of Minaprine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Peginterferon alfa-2b.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
MoclobemideThe serum concentration of Moclobemide can be decreased when it is combined with Peginterferon alfa-2b.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
muraglitazarThe serum concentration of muraglitazar can be increased when it is combined with Peginterferon alfa-2b.Investigational
NabumetoneThe serum concentration of Nabumetone can be increased when it is combined with Peginterferon alfa-2b.Approved
NaproxenThe serum concentration of Naproxen can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Peginterferon alfa-2b.Approved
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
NicergolineThe serum concentration of Nicergoline can be decreased when it is combined with Peginterferon alfa-2b.Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Peginterferon alfa-2b.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
Nitric OxideThe serum concentration of Nitric Oxide can be increased when it is combined with Peginterferon alfa-2b.Approved
NitrofuralThe serum concentration of Nitrofural can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Peginterferon alfa-2b.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Peginterferon alfa-2b.Approved
OxaliplatinThe serum concentration of Oxaliplatin can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
OxtriphyllineThe serum concentration of Oxtriphylline can be increased when it is combined with Peginterferon alfa-2b.Approved
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Peginterferon alfa-2b.Approved
ParoxetineThe serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegloticaseThe therapeutic efficacy of Peginterferon alfa-2b can be decreased when used in combination with Pegloticase.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Peginterferon alfa-2b.Withdrawn
PhenforminThe serum concentration of Phenformin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
PimozideThe serum concentration of Pimozide can be increased when it is combined with Peginterferon alfa-2b.Approved
PindololThe serum concentration of Pindolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PiperazineThe serum concentration of Piperazine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Peginterferon alfa-2b.Approved
ProcainamideThe serum concentration of Procainamide can be decreased when it is combined with Peginterferon alfa-2b.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Peginterferon alfa-2b.Approved
PromazineThe serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
PromethazineThe serum concentration of Promethazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
ProtriptylineThe serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PseudoephedrineThe serum concentration of Pseudoephedrine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Peginterferon alfa-2b.Approved
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Peginterferon alfa-2b.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Peginterferon alfa-2b.Approved
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Peginterferon alfa-2b.Approved
RemoxiprideThe serum concentration of Remoxipride can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
repinotanThe serum concentration of repinotan can be decreased when it is combined with Peginterferon alfa-2b.Investigational
ResveratrolThe serum concentration of Resveratrol can be increased when it is combined with Peginterferon alfa-2b.Experimental, Investigational
RibavirinThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ribavirin.Approved
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Peginterferon alfa-2b.Approved
RiluzoleThe serum concentration of Riluzole can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Peginterferon alfa-2b.Approved
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Peginterferon alfa-2b.Investigational, Withdrawn
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Peginterferon alfa-2b.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Peginterferon alfa-2b.Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Peginterferon alfa-2b.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Peginterferon alfa-2b.Approved
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Peginterferon alfa-2b.Approved
SparteineThe serum concentration of Sparteine can be decreased when it is combined with Peginterferon alfa-2b.Experimental
TacrineThe serum concentration of Tacrine can be increased when it is combined with Peginterferon alfa-2b.Withdrawn
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Peginterferon alfa-2b.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TapentadolThe serum concentration of Tapentadol can be decreased when it is combined with Peginterferon alfa-2b.Approved
TegaserodThe serum concentration of Tegaserod can be decreased when it is combined with Peginterferon alfa-2b.Investigational, Withdrawn
TelbivudineThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Telbivudine.Approved, Investigational
TelithromycinThe serum concentration of Telithromycin can be increased when it is combined with Peginterferon alfa-2b.Approved
TemafloxacinThe serum concentration of Temafloxacin can be increased when it is combined with Peginterferon alfa-2b.Withdrawn
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Peginterferon alfa-2b.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Peginterferon alfa-2b.Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ThalidomideThe serum concentration of Thalidomide can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Withdrawn
TheobromineThe serum concentration of Theobromine can be increased when it is combined with Peginterferon alfa-2b.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Peginterferon alfa-2b.Approved
ThiabendazoleThe serum concentration of Thiabendazole can be increased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ThiothixeneThe serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Peginterferon alfa-2b.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Peginterferon alfa-2b.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
TriamtereneThe serum concentration of Triamterene can be increased when it is combined with Peginterferon alfa-2b.Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Peginterferon alfa-2b.Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Peginterferon alfa-2b.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Peginterferon alfa-2b.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Peginterferon alfa-2b.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Peginterferon alfa-2b.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Peginterferon alfa-2b.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Peginterferon alfa-2b.Approved
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Peginterferon alfa-2b.Approved
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Peginterferon alfa-2b.Approved, Vet Approved
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Peginterferon alfa-2b.Approved
ZidovudineThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Zidovudine.Approved
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Peginterferon alfa-2b.Approved
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Peginterferon alfa-2b.Approved, Investigational
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Peginterferon alfa-2b.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Peginterferon alfa-2b.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesL03AB60L03AB10
AHFS Codes
  • 08:18.20
PDB Entries
FDA labelDownload (50.9 KB)
MSDSNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsule; powder, for solutionOral; Subcutaneous
Injection, powder, lyophilized, for solutionSubcutaneous120 ug/.5mL
Injection, powder, lyophilized, for solutionSubcutaneous150 ug/.5mL
Injection, powder, lyophilized, for solutionSubcutaneous50 ug/.5mL
Injection, powder, lyophilized, for solutionSubcutaneous80 ug/.5mL
Kit
Powder, for solutionSubcutaneous118.4 mcg
Powder, for solutionSubcutaneous177.6 mcg
Powder, for solutionSubcutaneous222 mcg
Powder, for solutionSubcutaneous74 mcg
Prices
Unit descriptionCostUnit
Peg-Intron Redipen Pak 4 4 50 mcg/0.5ml Kit Box2428.8USD kit
Peg-Intron Redipen 150 mcg/0.5ml Kit702.87USD kit
Peg-Intron 150 mcg Kit671.74USD kit
Peg-Intron Redipen 120 mcg/0.5ml Kit669.39USD kit
Peg-Intron redipen 150 mcg640.61USD redipen
Peg-Intron redipen 150 mcg 4pk640.6USD redipen
Peg-Intron 120 mcg Kit639.74USD kit
Peg-Intron Redipen 80 mcg/0.5ml Kit637.49USD kit
Peg-Intron redipen 120 mcg610.09USD redipen
Peg-Intron 80 mcg Kit609.26USD kit
Peg-Intron 50 mcg/0.5ml Kit607.19USD kit
Peg-Intron redipen 80 mcg581.02USD redipen
Peg-Intron 50 mcg kit553.4USD kit
Peg-Intron redipen 50 mcg553.4USD redipen
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341567 No2008-02-192025-02-19Canada
CA2329474 No0002-02-262016-10-31Canada
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point61 °CBeldarrain, A. et al., Biochemistry 38:7865-7873 (1999)
isoelectric point5.99Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Type i interferon receptor activity
Specific Function:
Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JAKs, TYK2, STAT proteins and IFNR alpha- and beta-subunits themselves. Can also transduce IFNB signals without the help of IFNAR2, and not activating the Jak-STAT pathway.
Gene Name:
IFNAR1
Uniprot ID:
P17181
Molecular Weight:
63524.81 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. [PubMed:15898717 ]
  4. Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3. [PubMed:19955815 ]
  5. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. [PubMed:16953837 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Type i interferon receptor activity
Specific Function:
Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase, JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity.
Gene Name:
IFNAR2
Uniprot ID:
P48551
Molecular Weight:
57758.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. [PubMed:15898717 ]
  4. Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3. [PubMed:19955815 ]
  5. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. [PubMed:16953837 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23